LarsenSKrogsgaardDGLarsenLAIachinaMSkyttheAFrederiksenH. Genetic and environmental influences in Dupuytren’s disease: A study of 30,330 Danish twin pairs. J Hand Surg Eur. 2015, 40:
2.
MaceyAC. Outcomes of hand surgery. British Society for Surgery of the Hand. J Hand Surg Br. 1995, 20: 841–55.
3.
PalmerKTD’AngeloSSyddallHGriffinMJCooperCCoggonD. Dupuytren’s contracture and occupational exposure to hand-transmitted vibration. Occup Environ Med. 2014, 71: 241–5.
4.
PeimerCAWilbrandSRAGerberRAChapmanDSzczypaP. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur. 2015, 40:
5.
RodriguesJNZhangWScammellBEDavisTRC. What patients want from the treatment of Dupuytren’s disease – is the Unité Rhumatologique des Affections de la Main (URAM) scale relevant?J Hand Surg Eur. 2015, 40 (in press).
6.
van RijssenALWerkerPM. Percutaneous needle fasciotomy for recurrent Dupuytren’s disease. J Hand Surg Am. 2012, 37: 1820–3.
7.
VerheydenJR. Early outcomes of a sequential series of 144 patients with Dupuytren’s contracture treated by collagenase injection using an increased dose, multi-cord technique. J Hand Surg Eur. 2015, 40:
8.
WarwickD. Collagenase Clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg Eur. 2015, 40 (in press).
